Research never stops

Topas Therapeutics GmbH

In March 2016 Evotec AG announced the formation of a spin-off company in the field of nanoparticle-based therapeutics to treat immunological disorders. Epidarex Capital, EMBL Ventures and Gimv participated together with Evotec in the € 14 m ($ 15.75 m) Series A round of Topas Therapeutics GmbH. Evotec will remain the largest shareholder after the financing round.

The new company, Topas Therapeutics GmbH (“Topas”), aims to build a unique pipeline of clinical-stage development projects to treat autoimmune diseases. The proceeds of the Series A funding enable Topas to expand and accelerate its proprietary liver-based tolerance induction platform and to progress with its own product development efforts in multiple autoimmune and inflammatory indications including multiple sclerosis into clinical proof-of-concept ("POC") stage. Pre-clinical development for multiple sclerosis is underway and Phase I studies in MS are expected to commence in 2017.

Topas’ unique platform is built on proprietary nanoparticles which selectively target liver sinusoidal endothelial cells (“LSECs”) and deliver peptides to such cells. LSECs are one of the body ́s premier sites to induce tolerance against blood borne antigens by generating peptide-specific regulatory T cells; this natural pathway is utilized by the Topas technology and applied to treat autoimmune diseases, allergies and drug induced immune reaction where the antigen and its respective antigenic peptides are known.

Topas emerges from the neuro portfolio of Bionamics GmbH which was acquired by Evotec in March 2014 and is an early-stage therapeutics company using ground breaking nanoparticle technology to target autoimmune and inflammatory diseases via the induction of antigen-specific immune tolerance in the liver. The platform has been exclusively licensed from the University Medical Center Hamburg-Eppendorf where it was invented by Johannes Herkel, Jörg Heeren and other colleagues in Hamburg.


For more information, please contact:

Dr Timm-H. Jessen
CEO/Managing Director

Topas Therapeutics GmbH
Fallenried 88, Haus B
20251 Hamburg (Germany)